Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

G6PD Deficiency Workup

  • Author: Lawrence C Wolfe, MD; Chief Editor: George T Griffing, MD  more...
 
Updated: Jul 28, 2015
 

Approach Considerations

Indications for testing for glucose-6-phosphatase dehydrogenase (G6PD) deficiency include the following:

  • Development of hemolysis after taking medications or experiencing conditions that  induce oxidative stress especially in patients of African, Mediterranean, or Asian descent.
  • Unexplained severe or prolonged neonatal hyperbilirubinemia with poor response to phototherapy.
  • Family history suggestive of G6PD deficiency especially among males.
  • Recurrent jaundice, splenomegaly, or cholelithiasis in patients of African, Mediterranean, or Asian descent. [3]  
  • Nonspherocytic hemolytic anemia (since the underlying cause might be severe G6PD deficiency and chronic hemolysis)
Next

Laboratory Studies

Hemolysis

Tests to diagnose hemolysis include the following:

  • Complete blood cell count (CBC) and reticulocyte count
  • Peripheral blood smear
  • Lactate dehydrogenase (LDH) level
  • Indirect and direct bilirubin level
  • Serum haptoglobin level
  • Urinalysis for hemoglobinuria
  • Urine hemosiderin 

Other causes of hemolysis and hemoglobinuria

Tests to rule out other causes of hemolysis and hemoglobinuria include the following:

Complete blood cell count will show mild to severe anemia depending on the G6PD variant and the type of oxidant stress. Increase in reticulocyte count represents bone marrow response to hemolysis by producing young red cells. Increase in indirect serum bilirubin and LDH indicate hemolysis. Low or absent haptoglobin levels, hemoglobinemia, hemoglobinuria, and presence of urinary hemosiderin indicate severe intravascular hemolysis, which is the main contributor to pathophysiology and diagnosis of G6PD deficiency. A part of hemolysis can be extracellular where damaged red cells are recognized as abnormal and undergo extravascular hemolysis by reticulo-enothelial system.[14]

On the peripheral smear, routine staining may reveal polychromasia, representing increased red blood cell production. Another typical feature is the presence of “hemighosts,” red cells that appear to have unevenly distributed hemoglobin, and  “bite cells” or “blister cells,” red cells that appear to have a portion of them bitten away. Blister cells are characteristic of acute hemolysis induced by oxidative stress.[16]

Denatured hemoglobin can be visualized as Heinz bodies in peripheral blood smears processed with supravital staining. Heinz bodies are shown in the figure below.

Heat stability and/or heat denaturation and high-performance liquid chromatography can be used to identify unstable hemoglobin and thereby rule out G6PD deficiency.

G6PD deficiency

Semi-quantitative tests:

  • Fluorescent spot test: This is a direct test that measures the generation of nicotinamide adenine dinucleotide phosphate (NADPH) from nicotinamide adenine dinucleotide phosphate (NADP); the test is positive if the blood spot fails to show fluorescence under ultraviolet light. It is rapid, simple, sensitive, and inexpensive. [30, 31, 32]  A variant of the spot test that can be interpreted by simple color change with naked eye examination is used for screening large populations in tropical areas and before starting treatment with antimalarial drugs, such as primaquine, in countries where G6PD deficiency and malaria are both endemic. The test is not reliable in heterozygous females.
  • Methemoglobin reduction test (MRT): This is a rapid indirect test that measures the reduced methemoglobin levels produced after NADPH oxidation. G6PD activity is assessed by first treating RBCs with nitrite (converting oxyhemoglobin [red] to methemoglobin [brown]), and then examining the rate of NADPH-dependent methemoglobin reduction in the presence of an appropriate redox catalyst (Nile blue or methylene blue) and substrate (glucose). [30]
  • Cytofluorimetric method: This is a cytochemical typing assay which provides a fluorometric readout of the classic methemoglobin reduction test (MRT) at the level of an individual red blood cell. This assay represents a useful addition to the screening and research toolkit for G6PD deficiency, especially in malaria-endemic areas. [31]

Quantitative test:

  • Spectrophotometric assay: Quantitative tests for G6PD activity are considered the criterion standard. The rate of NADPH generation is spectrophotometrically measured at a wavelength of 340 nm. The G6PD activity is finally expressed as G6PD IU/RBCs and G6PD IU/hemoglobin ratios. In normal red blood cells, the G6PD activity ranges from 7-10 IU/g Hb, when measured at 30 C. [30, 31, 32]  Testing for enzyme activity should not be performed during episodes of acute hemolysis, as results may be falsely negative. Senescent red blood cells are more vulnerable to hemolysis due to their diminished G6PD levels. Compensatory increase of immature young red cells with increased G6PD levels usually occurs in state of acute hemolysis, and hence results could be altered. 

Screening for G6PD deficiency

A semi-quantitative test is usually indicated in patients with a suggestive family history or in geographical areas with a high prevalence of the disorder. Positive screening results should be confirmed by quantitative tests. Diagnosis of G6PD may be difficult in females, who may be hemizygous or have skewed X chromosome inactivation or G6PD gene mosaicism.

G6PD activity is higher in premature infants than in term infants. This should be considered when testing for G6PD deficiency in infants.

Previous
Next

Imaging Studies

Abdominal ultrasound may be useful in assessing for splenomegaly and gallstones. These complications are typically limited to patients with severe chronic hemolysis.

Previous
Next

Other Tests

Genetic testing consists of DNA-based genotyping and sequencing, which helps in the identification of hundreds of mutations associated with G6PD deficiency worldwide, including many region-specific common variants. The molecular analysis may be useful for population screening, family studies, females, and prenatal diagnosis.

Previous
 
 
Contributor Information and Disclosures
Author

Lawrence C Wolfe, MD Associate Chief for Hematology and Safety, Division of Pediatric Hematology-Oncology, Cohen Children's Medical Center

Lawrence C Wolfe, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Association of Blood Banks, American Society of Hematology, Children's Oncology Group, Eastern Society for Pediatric Research

Disclosure: Nothing to disclose.

Coauthor(s)

Shilpa Shukla, MBBS Fellow in Pediatric Hematology/Oncology, North Shore-LIJ Cohen Children’s Medical Center

Shilpa Shukla, MBBS is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society of Pediatric Hematology/Oncology, Medical Council of India, Hemostasis and Thrombosis Research Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

George T Griffing, MD Professor Emeritus of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, International Society for Clinical Densitometry, Southern Society for Clinical Investigation, American College of Medical Practice Executives, American Association for Physician Leadership, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical and Translational Research, Endocrine Society

Disclosure: Nothing to disclose.

Additional Contributors

Frederick H Ziel, MD Associate Professor of Medicine, University of California, Los Angeles, David Geffen School of Medicine; Physician-In-Charge, Endocrinology/Diabetes Center, Director of Medical Education, Kaiser Permanente Woodland Hills; Chair of Endocrinology, Co-Chair of Diabetes Complete Care Program, Southern California Permanente Medical Group

Frederick H Ziel, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Endocrinology, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Federation for Medical Research, American Medical Association, American Society for Bone and Mineral Research, California Medical Association, Endocrine Society, International Society for Clinical Densitometry

Disclosure: Nothing to disclose.

Acknowledgements

Bernard Corenblum, MD, FRCP(C) Professor of Medicine, Director, Endocrine-Metabolic Testing and Treatment Unit, Ovulation Induction Program, Department of Internal Medicine, Division of Endocrinology, University of Calgary, Canada

Disclosure: Nothing to disclose. Gregory A Kline, MD Associate Professor, Department of Medicine, Division of Endocrinology, Richmond Road Diagnostic Centre, University of Calgary Faculty of Medicine, Canada

Gregory A Kline, MD is a member of the following medical societies: Canadian Medical Association and Christian Medical & Dental Society

Disclosure: Nothing to disclose.

Vasudevan A Raghavan, MBBS, MD, MRCP(UK) Director, Cardiometabolic and Lipid (CAMEL) Clinic Services, Division of Endocrinology, Scott and White Hospital, Texas A&M Health Science Center College of Medicine

Vasudevan A Raghavan, MBBS, MD, MRCP(UK) is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Heart Association, National Lipid Association, Royal College of Physicians, and The Endocrine Society

Disclosure: Nothing to disclose.

References
  1. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009 May-Jun. 42 (3):267-78. [Medline].

  2. Alving AS, Carson PE, Flanagan CL, Ickes CE. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science. 1956 Sep 14. 124 (3220):484-5. [Medline].

  3. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008 Jan 5. 371 (9606):64-74. [Medline].

  4. Mason PJ, Bautista JM, Gilsanz F. G6PD deficiency: the genotype-phenotype association. Blood Rev. 2007 Sep. 21 (5):267-83. [Medline].

  5. Kaplan M, Hammerman C. The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective. J Perinatol. 2009 Feb. 29 Suppl 1:S46-52. [Medline].

  6. Weng YH, Chiu YW. Clinical characteristics of G6PD deficiency in infants with marked hyperbilirubinemia. J Pediatr Hematol Oncol. 2010 Jan. 32 (1):11-4. [Medline].

  7. Dhillon AS, Darbyshire PJ, Williams MD, Bissenden JG. Massive acute hemolysis in neonates with glucose-6-phosphate dehydrogenase deficiency. Arch Dis Child Fetal Neonatal Ed. 2003. 88:F534-F536 doi:10.1136/fn.88.6.F534.

  8. Valaes T. Severe neonatal jaundice associated with glucose-6-phosphate dehydrogenase deficiency: pathogenesis and global epidemiology. Acta Paediatr Suppl. 1994 Mar. 394:58-76. [Medline].

  9. Kaplan M, Hammerman C. Severe neonatal hyperbilirubinemia. A potential complication of glucose-6-phosphate dehydrogenase deficiency. Clin Perinatol. 1998 Sep. 25 (3):575-90, viii. [Medline].

  10. Kaplan M, Hammerman C. Glucose-6-phosphate dehydrogenase deficiency: a hidden risk for kernicterus. Semin Perinatol. 2004 Oct. 28 (5):356-64. [Medline].

  11. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004 Jul. 114 (1):297-316. [Medline].

  12. Abid S, Khan AH. Severe hemolysis and renal failure in glucose-6-phosphate dehydrogenase deficient patients with hepatitis E. Am J Gastroenterol. 2002 Jun. 97 (6):1544-7. [Medline].

  13. Guan Y, Roter DL, Huang A, Erby LA, Chien YH, Hwu WL. Parental discussion of G6PD deficiency and child health: implications for clinical practice. Arch Dis Child. 2014 Mar. 99 (3):251-5. [Medline].

  14. Luzzatto L, Poggi V. Glucose-6-phosphate dehydrogenase deficiency. Orskin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux SE, eds. Nathan & Oski's Hematology of Infancy and Childhood. 7th ed. Philadelphia PA: Saunders; 2009. 883-907.

  15. Vulliamy TJ, Luzzato L. Glucose-6-phosphatase dehydrogenase deficiency and related disorders. Blood Principles and Practice of Hematology. 2nd ed. 2002.

  16. Luzzatto L. Hemolytic anemia and anemia due to blood loss. Harrison’s Principles of Internal Medicine. 18th ed. McGraw-Hill Professional Publishing; 2011.

  17. Kuzniewicz MW, Wickremasinghe AC, Wu YW, McCulloch CE, Walsh EM, Wi S, et al. Incidence, etiology, and outcomes of hazardous hyperbilirubinemia in newborns. Pediatrics. 2014 Sep. 134 (3):504-9. [Medline].

  18. Makarona K, Caputo VS, Costa JR, et al. Transcriptional and epigenetic basis for restoration of G6PD enzymatic activity in human G6PD-deficient cells. Blood. 2014 Jul 3. 124 (1):134-41. [Medline].

  19. Bautista JM. Epigenetic therapy reprograms hereditary disease. Blood. 2014 Jul 3. 124 (1):7-8. [Medline].

  20. Gomez-Gallego F, Garrido-Pertierra A, Bautista JM. Structural defects underlying protein dysfunction in human glucose-6-phosphate dehydrogenase A(-) deficiency. J Biol Chem. 2000 Mar 31. 275 (13):9256-62. [Medline].

  21. Oppenheim A, Jury CL, Rund D, Vulliamy TJ, Luzzatto L. G6PD Mediterranean accounts for the high prevalence of G6PD deficiency in Kurdish Jews. Hum Genet. 1993 Apr. 91 (3):293-4. [Medline].

  22. Cappellini MD, Martinez di Montemuros F, De Bellis G, Debernardi S, Dotti C, Fiorelli G. Multiple G6PD mutations are associated with a clinical and biochemical phenotype similar to that of G6PD Mediterranean. Blood. 1996 May 1. 87 (9):3953-8. [Medline].

  23. Martinez di Montemuros F, Dotti C, Tavazzi D, Fiorelli G, Cappellini MD. Molecular heterogeneity of glucose-6-phosphate dehydrogenase (G6PD) variants in Italy. Haematologica. 1997 Jul-Aug. 82 (4):440-5. [Medline].

  24. Cappellini MD, Sampietro M, Toniolo D, Carandina G, Martinez di Montemuros F, Tavazzi D, et al. G6PD Ferrara I has the same two mutations as G6PD A(-) but a distinct biochemical phenotype. Hum Genet. 1994 Feb. 93 (2):139-42. [Medline].

  25. Pinto FM, Gonzalez AM, Hernandez M, Larruga JM, Cabrera VM. Sub-Saharan influence on the Canary Islands population deduced from G6PD gene sequence analysis. Hum Biol. 1996 Aug. 68 (4):517-22. [Medline].

  26. Beutler E, Kuhl W, Vives-Corrons JL, Prchal JT. Molecular heterogeneity of glucose-6-phosphate dehydrogenase A-. Blood. 1989 Nov 15. 74 (7):2550-5. [Medline].

  27. Kurdi-Haidar B, Mason PJ, Berrebi A, Ankra-Badu G, al-Ali A, Oppenheim A, et al. Origin and spread of the glucose-6-phosphate dehydrogenase variant (G6PD-Mediterranean) in the Middle East. Am J Hum Genet. 1990 Dec. 47 (6):1013-9. [Medline].

  28. Karimi M, Martinez di Montemuros F, Danielli MG, Farjadian S, Afrasiabi A, Fiorelli G, et al. Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Fars province of Iran. Haematologica. 2003 Mar. 88 (3):346-7. [Medline].

  29. Betke K, Beutler E, Brewer GJ, et al. Standardization of procedures for the study of glucose-6-phosphate dehydrogenase: report of a WHO Scientific Group. World Health Organ Tech Rep Ser. 1967. 366:1-53.

  30. Minucci A, Giardina B, Zuppi C, Capoluongo E. Glucose-6-phosphate dehydrogenase laboratory assay: How, when, and why?. IUBMB Life. 2009 Jan. 61 (1):27-34. [Medline].

  31. Shah SS, Diakite SA, Traore K, Diakite M, Kwiatkowski DP, Rockett KA, et al. A novel cytofluorometric assay for the detection and quantification of glucose-6-phosphate dehydrogenase deficiency. Sci Rep. 2012. 2:299. [Medline].

  32. Domingo GJ, Satyagraha AW, Anvikar A, et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malar J. 2013 Nov 4. 12:391. [Medline].

  33. Au WY, Ngai CW, Chan WM, Leung RY, Chan SC. Hemolysis and methemoglobinemia due to hepatitis E virus infection in patient with G6PD deficiency. Ann Hematol. 2011 Oct. 90 (10):1237-8. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.